NKGen Presents Troculeucel Data at CTAD 2026

NKGen Biotech will share long-term follow-up data on troculeucel in one patient with moderate Alzheimer's disease at a November conference.

Updated on Nov. 9, 2026 in Alzheimer’s

Clear glass cell culture flasks with pale amber liquid rest on a stainless steel laboratory bench under cool, even light.
NKGen Biotech will present long-term follow-up data on its troculeucel immunotherapy in one patient with moderate Alzheimer's disease at a November 16 conference. AI Illustration. Upload story photo >

NKGen Biotech will present a poster on the long-term follow-up of troculeucel in moderate Alzheimer's disease at the 19th Clinical Trials on Alzheimer's Disease Conference on November 16, 2026. The poster describes one patient who received troculeucel in a Phase 1 study and then continued in an open-label extension study.

Why it matters

The presentation offers an early look at how a cell-based immunotherapy may affect cognition over an extended treatment period in moderate Alzheimer's disease. Because the data come from a single patient, they cannot establish broader effectiveness.

The poster reports observations from one patient who received an additional 12 months of treatment after the Phase 1 study. The extraction provides no control group or broader patient sample, so the findings cannot be generalized.

The players

NKGen Biotech

NKGen Biotech is a clinical-stage biotechnology company headquartered in Santa Ana, California, developing cell-based therapies for neurodegenerative disease.

Clinical Trials on Alzheimer's Disease Conference

The Clinical Trials on Alzheimer's Disease conference is a major annual scientific meeting where researchers present clinical trial results in the field.

The details

The poster, titled 'Long-Term Cognitive Benefit of Troculeucel NK Cell Therapy in a Patient With Moderate Alzheimer's Disease: A Single-Subject Analysis,' will explore the patient's cognitive outcomes over the extended period. Troculeucel is a cell-based, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate, and the World Health Organization has approved it as the International Nonproprietary Name for SNK01.

Timeline

  1. November 16, 2026, 2:00 p.m. ET: Poster Session 1 begins for the troculeucel presentation.

  2. November 17, 2026, 5:30 p.m. ET: Poster Session 1 ends.

  3. November 16-19, 2026: CTAD 2026 takes place in Boston and virtually.

Health Landscape

Troculeucel is a patient-specific, ex vivo expanded autologous NK cell therapy, a platform that has largely been explored in oncology and is now being tested in neurodegeneration. This single-patient report extends that approach into moderate Alzheimer's disease, where few disease-modifying options exist.

Because this is a single-patient report from an early-stage study, the results do not change available treatment options for people with Alzheimer's today. Readers interested in clinical research participation should check eligibility and trial availability with their physician.

The takeaway

A single patient's cognitive course is an early signal rather than proof of benefit, so the conference data will matter most once larger studies report. Readers should treat the findings as preliminary until controlled trial results are available.

What happens next

NKGen Biotech's poster will be presented in Poster Session 1 at CTAD 2026 from November 16 through November 17, 2026.

Further reading

For more on the disease at the center of this research, see our Alzheimer's coverage.